Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Drug Metabolism and Transport
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1498339
This article is part of the Research Topic New Drugs and Future Challenges in Drug Metabolism and Transport View all 11 articles

Development of a UPLC-MS/MS method for the determination of Sulfatinib and its no interaction with myricetin in rats

Provisionally accepted
Dongxin Chen Dongxin Chen 1Jie Chen Jie Chen 2Hailun Xia Hailun Xia 2Xiaohai Chen Xiaohai Chen 2Jinyu Hu Jinyu Hu 2Guangliang Wu Guangliang Wu 1*Xuegu Xu Xuegu Xu 3*
  • 1 Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang Province, China
  • 2 First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
  • 3 Affiliated Eye Hospital to Wenzhou Medical University, Wenzhou, China

The final, formatted version of the article will be published soon.

    Sulfatinib is a novel oral tyrosine kinase inhibitor (TKI) with selective inhibition of fibroblast growth factor (FGFR), colony-stimulating factor 1 receptor (CSF-1R) and vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3. It has been approvedfor the therapy of neuroendocrine tumors arising in the non-pancreatic (December 2020) and pancreatic (June 2021) glands. Until now, there has no research on the determination of sulfatinib in biological medium by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method. The current study validated a sensitive and reliable quantitative detection of sulfatinib in plasma using UPLC-MS/MS for the first time, and investigated the interaction with myricetin in rats. Acetonitrile was used to precipitate the plasma protein, and lenvatinib was employed as the internal standard (IS). The method demonstrated that sulfatinib presented high linearity over the concentration of 1-2000 ng/mL with the lower limit of quantification (LLOQ) of 1 ng/mL. It was validated methodologically that the precision, matrix effect, stability, accuracy and extraction recovery were all within the allowable values. Moreover, male Sprague-Dawley (SD) rats were assigned randomly to assess the interaction between sulfatinib (30 mg/kg) and myricetin (50 mg/kg). Nevertheless, no significant differences of the main pharmacokinetic parameters were revealed. This may be due to insufficient doses of myricetin, or failure of myricetin to act in a timely manner in vivo. The findings contributed to a better understanding of the metabolism and drug-drug interaction of sulfatinib, but the presence or absence of interactions needs to be confirmed by further studies.

    Keywords: sulfatinib, Myricetin, Drug-Drug Interaction, pharmacokinetics, UPLC-MS/MS

    Received: 18 Sep 2024; Accepted: 15 Nov 2024.

    Copyright: © 2024 Chen, Chen, Xia, Chen, Hu, Wu and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Guangliang Wu, Ningbo Medical Centre Lihuili Hospital, Ningbo, 315010, Zhejiang Province, China
    Xuegu Xu, Affiliated Eye Hospital to Wenzhou Medical University, Wenzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.